Drugs / GTX-B001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07181369 | Oct 2025 → Aug 2027 expected | chronic inducible urticaria, cold urticaria | Granular Therapeutics Limited | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GTX-B001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07181369 ↗ |
| Route | Intravenous | “GTX-B001 will be administered intravenously on Day 1” NCT07181369 ↗ |